Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-04-15

Clinical Trial Update: The HAM Infliximab Study [Phase 2]

View source ↗

Summary

A Phase 2 trial of infliximab for HTLV-I-associated myelopathy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Infliximab (infliximab)

Snippet

Sponsor: Imperial College London | Conditions: HTLV-I-associated Myelopathy | Phase 2 | Status: TERMINATED